FINHUB Insights

MDT · Q4 FY26 · Jan 24 – Apr 24, 2026

Medtronic Q4 FY26: where the revenue came from and where it went

Medtronic Q4 FY26: revenue $9.8B (+10% year over year). Net profit $1.2B. Largest cohort Cardiovascular $3.8B. The whole income statement as a sankey diagram from the SEC filing.

Period
Jan 24 – Apr 24, 2026
Reported
Jun 18, 2026 10-K
Sankey diagram of Medtronic's income statement for Q4 FY26: revenue of $9.8 billion splits into segments and flows out into costs, taxes and net profit.

Tap the diagram to enlarge · figures in billions of dollars

Revenue$9.8B +10% year over year
Gross profit$6.4B 65% margin
Operating profit$1.9B 19% margin
Net profit$1.2B 13% margin

The numbers

All figures in billions of U.S. dollars, for Q4 FY26 (period ends Apr 24, 2026).
ItemValueShare of revenueYear over year
Revenue 9.8 100% +10%
Cardiovascular 3.8 39% +14%
Neuroscience Group 2.8 29% +5%
Medical Surgical 2.4 24% +8%
Diabetes Group 0.8 8% +15%
Cost of revenue−3.435%
Gross profit6.465% margin+1pp
SG&A−3.131%+1pp
Other−1.515%+0pp
Operating profit1.919% margin+3pp
Tax−0.6
Interest & other costs−0.1
Net profit1.213%+1pp
Filing on EDGAR More quarters of MDT

Source of the numbers: structured XBRL data from the filing (10-K). The diagram is generated automatically and checked against EDGAR before release. The fourth quarter has no column of its own in an annual report, so it is the full year minus the first nine months. How we calculate it → About and methodology.

Older quarters